SEC Comment Letter 0000000000-24-006693 to Iterum Therapeutics plc (ITRM) (CIK 0001659323) (ITRM)
Iterum Therapeutics plc (ITRM) (CIK 0001659323)
Date: June 11, 2024 · CIK: 0001659323 · Accession: 0000000000-24-006693
AI Filing Summary & Sentiment
File numbers found in text: 333-280045
Letter
United States securities and exchange commission logo June 11, 2024 Corey N. Fishman President and Chief Executive Officer Iterum Therapeutics plc 200 South Wacker Drive, Suite 3100 Chicago, Illinois 60606 Re:Iterum Therapeutics plc Registration Statement on Form S-1 Filed June 7, 2024 File No. 333-280045 Dear Corey N. Fishman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian A. Johnson, Esq.
Show Raw Text
United States securities and exchange commission logo
June 11, 2024
Corey N. Fishman
President and Chief Executive Officer
Iterum Therapeutics plc
200 South Wacker Drive, Suite 3100
Chicago, Illinois 60606
Re:Iterum Therapeutics plc
Registration Statement on Form S-1
Filed June 7, 2024
File No. 333-280045
Dear Corey N. Fishman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian A. Johnson, Esq.